⌕
United Therapeutics · UTHR · Nasdaq
Tenet 72 · Solid
Compare
$584.10−0.64%At closeTenet 72 · Solid
$584.10−3.78 (−0.64%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

United Therapeutics (UTHR) Stock

United Therapeutics (UTHR) closed at $584.10 on Nov 17, 2026; its Tenet Score is 72 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

6 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$584.10
Nov 17, 2026
Market cap
$25.0B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
21.6×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
455.63 – 614.23
low → high · as of close, Nov 16, 2026
Tenet Score
72/100
Solid · 340 Healthcare peers

Industry: Drugs

United Therapeutics Corp scores 72/100. Solid. Strongest on quality and financial health, trading at 22× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
72/ 100
Solid
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
59
Quality
78
Health
78
Growth
75

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueCQualityBHealthBGrowthBMomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
4.0×
Sep 30, 2026 balance sheet
P/S
7.9×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
19%
TTM through Sep 30, 2026
Operating margin
46.9%
fiscal 2025, before interest and tax
Net margin
38.6%
TTM through Sep 30, 2026
Current ratio
4.61
Sep 30, 2026 balance sheet
Net debt / EBITDA
−1.5×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. Its co…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 271 US ETFs · top wrappers by weightSee all ETFs holding UTHR →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

CompanyTenet ScoreMarket cap
Biogen IncBIIB40$37.2B
Revolution Medicines IncRVMD39$36.1B
Zoetis IncZTS59$34.3B
Illumina IncILMN52$29.9B
Roivant Sciences LtdROIV43$28.0B
Insmed IncINSM33$27.0B
Incyte Corp.INCY60$24.5B
Alnylam Pharmaceuticals IncALNY52$21.4B
Medpace Holdings IncMEDP59$18.1B
Ascendis Pharma A/SASND53$16.8B

Compare United Therapeutics with

What sector and industry is United Therapeutics in?

United Therapeutics is in the Healthcare sector and the Drugs industry.

What is United Therapeutics' Tenet Score?

United Therapeutics' Tenet Score is 72 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.